by Truveta staff | Jun 17, 2024 | Data, News, Technology
Truveta now offers regulatory and audit capabilities to support our customers for real-world evidence (RWE) submissions to the Food and Drug Administration (FDA) and other global regulatory authority decisions. These regulatory grade capabilities advance Truveta’s...
by Truveta staff | May 28, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased throughout the first quarter of 2024 (+20.9% increase in March 2024 compared to December 2023). First-time prescribing rates (first-time GLP-1 RA prescriptions per total...
by Truveta staff | May 1, 2024 | News
Truveta Data delivers complete EHR data, including clinician notes and images, from more than 30 health systems, linked with SDOH, mortality and claims data, for scientifically rigorous research. Truveta Data provides regulatory grade, daily updated data from more...
by Truveta staff | Apr 4, 2024 | Data
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion provides a pathway for recouping costs associated with the device development process by...
by Truveta staff | Apr 2, 2024 | Data
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
